عرض بسيط للتسجيلة

المؤلفEl Kahlout, Reham Awni
المؤلفCoyle, Peter V.
المؤلفDargham, Soha R.
المؤلفChemaitelly, Hiam
المؤلفKacem, Mohamed Ali Ben Hadj
المؤلفAl-Mawlawi, Naema Hassan Abdulla
المؤلفGilliani, Imtiaz
المؤلفYounes, Nourah
المؤلفAlKanaani, Zaina
المؤلفAlKhal, Abdullatif
المؤلفALKuwari, Einas
المؤلفJeremijenko, Andrew
تاريخ الإتاحة2022-09-01T09:33:44Z
تاريخ النشر2022-01
اسم المنشورPLoS ONE
المعرّفhttp://dx.doi.org/10.1371/journal.pone.0262897
الاقتباسCoyle, P. V., El Kahlout, R. A., Dargham, S. R., Chemaitelly, H., Kacem, M. A. B. H., Al-Mawlawi, N. H. A., ... & Abu-Raddad, L. J. (2022). Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2. PloS one, 17(1), e0262897.‏
معرّف المصادر الموحدhttp://hdl.handle.net/10576/33630
الملخصThis study investigated the performance of a rapid point-of-care antibody test, the BioMedomics COVID-19 IgM/IgG Rapid Test, in comparison with a high-quality, validated, laboratory-based platform, the Roche Elecsys Anti-SARS-CoV-2 assay. Serological testing was conducted on 709 individuals. Concordance metrics were estimated. Logistic regression was used to assess associations with seropositivity. SARS-CoV-2 seroprevalence was 63.5% (450/709; 95% CI 59.8%-67.0%) using the BioMedomics assay and 71.9% (510/709; 95% CI 68.5%-75.2%) using the Elecsys assay. There were 60 discordant results between the two assays, all of which were seropositive in the Elecsys assay, but seronegative in the BioMedomics assay. Overall, positive, and negative percent agreements between the two assays were 91.5% (95% CI 89.2%-93.5%), 88.2% (95% CI 85.1%-90.9%), and 100% (95% CI 98.2%-100%), respectively, with a Cohen’s kappa of 0.81 (95% CI 0.78–0.84). Excluding specimens with lower (Elecsys) antibody titers, the agreement improved with overall, positive, and negative percent concordance of 94.4% (95% CI 92.3%-96.1%), 91.8% (95% CI 88.8%-94.3%), and 100% (95% CI 98.2%-100%), respectively, and a Cohen’s kappa of 0.88 (95% CI 0.85–0.90). Logistic regression confirmed better agreement with higher antibody titers. The BioMedomics COVID-19 IgM/IgG Rapid Test demonstrated good performance in measuring detectable antibodies against SARS-CoV-2, supporting the utility of such rapid point-of-care serological testing to guide the public health responses and vaccine prioritization. © 2022 Coyle et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
اللغةen
الناشرPublic Library of Science
الموضوعcoronavirus disease 2019
young adult
point of care testing
العنوانAssessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2
النوعArticle
رقم العدد1
رقم المجلد17
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة